Home > Boards > US OTC > Delisted > CardioVascular BioTherapeutics (fka CVBT)

<u>Venturis Therapeutics finally acknowledges CATASTROPHIC ADVERSE JUDGMENT</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
walhall Member Profile
Followed By 0
Posts 334
Boards Moderated 1
Alias Born 09/15/16
160x600 placeholder
DOT, DOJ Call for More Competition at Newark-Liberty Airport
The U.S. Department of Transportation plans to identify a single low-cost or ultra-low-cost airline to operate 16 peak afternoon and evening runway timings at Newark-Liberty International Airport.
Top Company News of the Day
Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Individuals
Corn Drops on Weak Export Sales -- Daily Grain Highlights
Front Month Nymex RBOB Gasoline Fell 1.15% to Settle at $2.1812 -- Data Talk
Front Month Nymex Natural Gas Fell 2.29% to Settle at $5.3350 -- Data Talk
DAX Ends 0.23% Higher at 15651.75 -- Data Talk
FTSE 100 Index Ends 0.16% Higher at 7027.48 -- Data Talk
STOXX Europe 600 Index Ends 0.44% Higher at 465.95 -- Data Talk
EURO STOXX 50 Index Ends 0.58% Higher at 4169.87 -- Data Talk
STOXX Europe 50 Index Ends 0.22% Higher at 3552.69 -- Data Talk
CAC 40 Index Ends 0.59% Higher at 6622.59 -- Data Talk
FTSE 100 Rises on Speculation over UK's Travel Restrictions Removal
Just Group Refinances via Issue of GBP325 Million in Sustainability Bonds
Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Since April 2018 -- Data Talk
T-Mobile Down 10 Straight Days, on Track for Record Losing Streak -- Data Talk
Lukoil, Gazprom Neft Create Joint Venture to Develop Siberian Oil and Gas Cluster
Volkswagen's Skoda Stops Production at Czech Sites Due to Chip Shortage
Dominion Energy Virginia Proposes New Solar, Energy Storage Projects
Consumer Sentiment Expected to Rise -- Data Week Ahead
VC Daily: Venture Capitalists Push Back Against Drug-Pricing Bill
Maersk Raises 3Q, 2021 Earnings Targets on Higher Freight Rates
Neovasc Gets FDA Approval for Reducer Clinical Trial
FTSE Rises, THG Shares Fall After 1st Half Loss as Shake-Up Looms
Manufacturing Activity in Philly Fed's District Accelerated in September
walhall   Saturday, 06/27/20 05:27:56 AM
Re: None
Post # of 3604 
Venturis Therapeutics finally acknowledges CATASTROPHIC ADVERSE JUDGMENT

Well, it finally happened. Venturis Therapeutics finally acknowledged that it suffered a catastrophic adverse judgment in February 2020 in the Dan Montano case. How do we know this? Well, for those of us with good memories, shortly afterwards, Venturis Therapeutics posted a defiant press release on its website that apparently bore little resemblance to the judge's actual ruling (as I've heard through my Venturis Therapeutics sources). If one read the company's press release one would think this was much ado about nothing, not a catastrophic 7-figure adverse judgment the company can not pay. And the echo chamber on here has only amplified that moronic conclusion (or is it an alcoholic one?).

But guess what? Mysteriously as we inch towards a final $,$$$,$$$ determination from the judge (that's 7-figures for those sober enough to count), that press release has magically vanished from Venturis Therapeutics's website. Poof! Just like the press release on October 2, 2018 announcing the new Chief Medical Officer Dr. Ori Ben-Yehuda, who left the company soon thereafter, resulting in the press release suddenly and mysteriously disappearing from the company's website without explanation, turning Dr. Ben-Yehuda overnight into a non-person.

But thanks to the Vecho chamber (the Venturis Therapeutics echo chamber), the Venturis Therapeutics press release touting its "victory" in this lawsuit has been preserved on this message board. I want to thank johnnyblades2001 and SlalomKing, among others, for repeatedly re-posting this message, thus preserving it forever even if Venturis Therapeutics wanted it to quietly go away. Thanks to their diligence and hard work, I am able to copy it in below:

In the Interim Decision handed down on February 25th by the Arbitrator, Michael Zimmerman, the Arbitrator found that Montano and/or Jacobs had plagiarized Venturis’ reports, made misleading statements to investors, infringed on Venturis’ copyrights and contractually breached their agreements and duties to Venturis. Due to the delay in Venturis bringing this action, complicated by the Montano Chapter 7 Bankruptcy Filing, and the ruling as to lack of sufficient evidence of damages, Venturis was awarded only a nominal amount of attorney fees. The Arbitrator also found that Montano and Jacobs were due some amount of the back salary from Venturis that they were claiming, stemming from working at Venturis from early 2012 through the middle of 2013; however, the amount due to Montano and Jacobs is less than the outstanding legal Judgment against Montano held by affiliates of Venturis.

I'd like to also thank Venturis Therapeutics for their integrity acknowledging this undeniable fact--by trying to erase it. Nothing speaks louder than actions. Once the judge issues his exact 7-figure determination, I'm hearing the rumor that collection efforts aggressively commence. It's over, folks. Goodbye Venturis Therapeutics.

The only question in my mind is, does the company get liquidated by Dan Montano, or by a court--assuming it files for bankruptcy? There is no hope for survival because this is a company with no revenues and no products on the market. Its fate was sealed in February 2020. Actually long before that, but we'll save that for another message, or upcoming quiz question.

For more information:

And to hear more from a Venturis insider who spilled the beans:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences